Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 1,797 matching trials from the live ClinicalTrials.gov search.
Terminated Phase 1Phase 2 Interventional Results available

Macular Pigment and Visual Performance in Glaucoma Patients

NCT03959592
Conditions
Glaucoma
Interventions
Lutein, zeaxanthin and mesozeaxanthin, Placebo
Drug · Other
Lead sponsor
Felipe Medeiros, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
COVID-19
Interventions
Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment
Biological · Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and PK of Nikkomycin Z in Healthy Subjects

NCT00834184
Conditions
Healthy
Interventions
nikkomycin Z
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Long COVID, Long COVID-19, Long COVID19
Interventions
BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE, tDCS-active, tDCS-sham
Other · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 20 more
Conditions
Type 1 Diabetes
Interventions
Estradiol, medroxyprogesterone, hydrocortisone, GH, Matching placebo
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Santa Barbara, California
Completed Phase 2Phase 3 Interventional Results available

Understanding Cognition, Oxytocin & Pain in Elders

NCT03878589
Conditions
Knee Osteoarthritis, Osteoarthritis
Interventions
Oxytocin (OT), Placebo (P)
Drug
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 100 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Gainesville, Florida
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-68179280 in Healthy Participants

NCT04844463
Conditions
Healthy
Interventions
JNJ-68179280, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Autism Spectrum Disorder
Interventions
Behavioral Therapy, Aripiprazole, Placebo
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
5 Years to 11 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cataract Monitored Anesthesia Care (MAC) Feasibility Pilot Study

NCT06506669
Conditions
Cataract, Bilateral Senile Cataract, Anesthesia, Patient Satisfaction
Interventions
Oral sedation, Placebo
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
BPD - Bronchopulmonary Dysplasia, Apnea of Prematurity, Hemodynamic Instability, Intubation
Interventions
Caffeine Citrate, Placebo (Normal Saline)
Drug
Lead sponsor
Jennifer Shepherd
Other
Eligibility
Up to 1 Day
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Los Angeles, California
Conditions
Non-Insertional Achilles Tendinopathy
Interventions
Dry needling, Sham dry needling
Other
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Conditions
Depression
Interventions
Traditional Attention Bias Modification, Gamified Attention Bias Modification, Sham Attention Bias Modification
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 70 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Austin, Texas
Conditions
Pediatric Pulmonary Hypertension
Interventions
Mono-Therapy with Sildenafil, Duo-Therapy with Sildenafil + Bosentan
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Months to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Aurora, Colorado • St. Petersburg, Florida • Baltimore, Maryland + 7 more
Terminated Not applicable Interventional Accepts healthy volunteers

Donepezil Memory Preservation Post ECT

NCT02331771
Conditions
Memory Impairment
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Porter Adventist Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Traumatic Brain Injury, Aging Related Cognitive Decline
Interventions
Active tDCS and Cognitive Training Intervention, Sham tDCS and Cognitive Training Intervention
Combination Product
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 2 Interventional Results available

Early Intervention With Fluoxetine in Autism

NCT00183339
Conditions
Autistic Disorder
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Months to 58 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Conditions
Dry Eye Disease (DED)
Interventions
Active Comparator EBI-005, Placebo Comparator
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
45
States / cities
Chandler, Arizona • Mesa, Arizona • Little Rock, Arkansas + 38 more
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
D-serine, placebo, Sensory Based remediation paradigm
Drug · Behavioral
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Orangeburg, New York
Completed Phase 2 Interventional Results available

Milrinone in Congenital Diaphragmatic Hernia

NCT02951130
Conditions
Congenital Diaphragmatic Hernia, Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure, Pulmonary Hypoplasia
Interventions
Milrinone, Placebo (5% Dextrose)
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
0 Hours to 168 Hours
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 15 more
Conditions
Alcohol Use Disorder (AUD)
Interventions
Tirzepatide, Placebo, [11C]raclopride plus drug, [11C]NNC-112
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Major Depressive Disorder
Interventions
Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome

NCT07218653
Conditions
Metabolic Syndrome
Interventions
Indomethacin, Placebo, MRI
Drug · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Stress
Interventions
Placebo, Oxytocin Intranasal Spray 12 International Unit (12IU), Oxytocin Intranasal Spray 24 International Unit (24IU), Functional MRI
Drug · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Omaha, Nebraska
Completed Phase 2 Interventional Results available

AFQ056 for Language Learning in Children With FXS

NCT02920892
Conditions
Fragile X Syndrome
Interventions
AFQ056, Placebo, Language Intervention
Drug · Other
Lead sponsor
Elizabeth Berry-Kravis
Other
Eligibility
32 Months to 6 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
14
States / cities
Davis, California • Denver, Colorado • New Haven, Connecticut + 11 more